Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type b (Hib) conjugate vaccine in Hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: A study in a rat model

Journal of Infectious Diseases

Volumn 191, Issue 1, 2005, Pages 58-64

  Mawas, Fatme ^a   Newman, Gareth ^a   Burns, Samantha ^a   Corbel, Michael J ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZA TYPE B CAPSULAR POLYSACCHARIDE; HAEMOPHILUS INFLUENZAE TYPE B TETANUS A VACCINE; HAEMOPHILUS INFLUENZAE TYPE B TETANUS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE ANTIBODY; POLYSACCHARIDE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CYTOKINES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE ACTIVATION; POLYSACCHARIDES; POLYSACCHARIDES, BACTERIAL; RATS; RATS, SPRAGUE-DAWLEY; TETANUS TOXOID; VACCINATION; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 11144311965     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/426396     Document Type: Article

References (26)

1. Mulholland EK, Hoestermannn A, Ward JI, Maine N, Ethevenaux C, Greenwood BM. The use of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine mixed with diphtheria-tetanus-pertussis vaccine in Gambian infants. Vaccine 1996; 14:905-9.
2. Cherian T, Niranjan T, Raghupathy P, Durot I, Dutta A. Safety and immunogenicity of Haemophilus influenzae type B vaccine given in combination with DTwP at 6, 10 and 14 weeks of age. Indian Pediatr 2002; 39: 427-36.
3. Eskola I, Ward I, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus- pertussis containing acellular pertussis. Lancet 1999; 354:2063-8.
4. Slack MH, Schapira D, Thwaites RJ, et al. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J Infect Dis 2001; 184:1617-20.
5. Pichichero ME, Passador S. Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine. Clin Infect Dis 1997; 25:1378-84.
6. Halperin SA, King I, Law B, Mills E, Willems P. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis 1999; 28:995-1001.
7. Daum RS, Zenko CE, Given GZ, Ballanco GA, Parikh H, Germino K. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J Infect Dis 2001; 184:1293-9.
8. Lee CY, Thipphawong I, Huang LM, et al. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics 1999; 103:25-30.
9. Lagos R, Kotloff K, Hoffenbach A, et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr Infect Dis J 1998; 17:294-304.
10. Mills E, Gold R, Thipphawong J, et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at two, four and six months of age. Vaccine 1998; 16:576-85.
11. McVernon I, Andrews N, Slack MPE, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361:1521-3.
12. Brenneman G, Silimperi D, Ward J. Recurrent invasive Haemophilus influenzae type b disease in Alaskan Natives. Pediatr Infect Dis J 1987; 6: 388-92.
13. Claesson BO, Trollfors B, Lagergard T, et al. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month old children. J Pediatr 1988; 112:695-702.
14. Sturgess AW, Rush K, Charbonneau RJ, et al. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Vaccine 1999; 17:1169-78.
15. Schutze MP, Deriaud E, Przewlock G, et al. Carrier-induced epitopic suppression is initiated through clonal dominance. J Immunol 1989; 142:2635-40.
16. Fusco PC, Michon F, Laude-Sharp M, et al. Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine. Vaccine 1998; 16:1842-9.
17. Gupta RK, Anderson R, Cecchini D, et al. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and Haemophilus influenzae type b capsular polysaccharide conjugate vaccine. Biologicals 1999; 27:167-76.
18. Madore DV, Anderson P, Baxter BD, et al. Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 1996; 3:84-8.
19. Noelle RJ, Marshall L, Roy M, et al. Role of contact and soluble factors in the growth and differentiation of B cells by helper T cells. Adv Exp Med Biol 1992; 323:131-8.
20. + T cells. Eur J Immunol 1991; 21:1187-94.
21. Gracie IA, Bradely IA. Interleukin-12 induces interferon-γ dependent switching of IgG alloantibodies subclass. Eur J Immunol 1996; 26: 1217-21.
22. Philips JR, Brouwer W, Edwards M, Mahler S, Ruhno J, Collins AM. The effectiveness of different rat IgG subclasses as IgE-blocking antibodies in the rat basophil leukaemia cell model. Immunol Cell Biol 1999; 77:121-6.
23. Dagan R, Eskola I, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneous to infants. Infect Immun 1998; 66:2093-8.
24. Lavigne MV, Castro M, Mateo N, et al. Whole-cell Bordetella pertussis vaccine component modulates the mouse immune response to an unrelated soluble antigen. Microbes Infect 2002; 4:815-20.
25. Fischer JE, Johnson TR, Peebles RS, Graham BS. Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge. J Infect Dis 1999; 180:714-9.
26. McGuirk P, Johnson PA, Ryan EJ, Mills KHG. Filamentous hemagglutinin and pertussis toxin from Bordetella pertussis modulate immune responses to unrelated antigens. J Infect Dis 2000; 182:1286-8.